Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.

about

ERRα suppression enhances the cytotoxicity of the MEK inhibitor trametinib against colon cancer cells Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer

P2860

Q58763293-CF24C396-DDA7-476A-820D-3CCA8288728E Q58806326-57C609DC-DFBE-456D-97DA-175959AFD7B0

P2860

Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.

Item

http://www.wikidata.org/entity/Q38705350

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Oncogenic KRAS-associated gene ...... strategy in colorectal cancer.

@en

type

Item

label

Oncogenic KRAS-associated gene ...... strategy in colorectal cancer.

@en

prefLabel

Oncogenic KRAS-associated gene ...... strategy in colorectal cancer.

@en

P1476

Oncogenic KRAS-associated gene ...... strategy in colorectal cancer.

@en

P2093

F Zhang

http://www.w3.org/2001/XMLSchema#string

J Li

http://www.w3.org/2001/XMLSchema#string

J Zheng

http://www.w3.org/2001/XMLSchema#string

M Gong

http://www.w3.org/2001/XMLSchema#string

M Pek

http://www.w3.org/2001/XMLSchema#string

S M J M Yatim

http://www.w3.org/2001/XMLSchema#string

X Jiang

http://www.w3.org/2001/XMLSchema#string

X Wu

http://www.w3.org/2001/XMLSchema#string

Y Chen

http://www.w3.org/2001/XMLSchema#string

P2860

A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models

Cell cycle, CDKs and cancer: a changing paradigm

DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications

Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene

FOXM1: an emerging master regulator of DNA damage response and genotoxic agent resistance

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.

P2888

onc.2017.120

P304

4975-4986

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/ONC.2017.120

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Qiang Yu

P577

2017-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085098354

http://www.w3.org/2001/XMLSchema#string

P698

28459468

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.

about

P2860

P2860

Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P921